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0.59 mmHg (95%CI, 0.09 to 1.09). However, in two-pollutant model
(PM2.5, BC), only IQR increases in 1-day(0.57 mmHg, 95%CI, 0.18 to
0.96) average BC was related signiﬁcantly with SBP, and 5-day average
BC (0.49 mmHg, 95% CI, 0.11 to 0.87) with DBP.
CONCLUSIONS In conclusion, our study suggests that PM2.5 and BC
are related with blood pressure of pregnant women in China, repre-
senting possibly increased risk of HDP. BC was more strongly associ-
ated with BP of pregnancy. In vitro and vivo studies also reported that
BC stimulates reactive oxygen species production and cytokine-
mediated inﬂammation, which may play a role in the BP and HDP. Our
study suggests combustion associated particles are particularly
important in China. Black carbon should be considered as one of the
air quality indicators in China.
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OBJECTIVES This study was intended to evaluate the efﬁcacy and
safety of Tongxinluo capsule for hypertension.
METHODS We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in the Cochrane Library, MEDLINE, Chinese Bio-Medical
Literature Database (CBM), Chinese National Knowledge Infrastructure
(CNKI), Wan-fang Data started from the ﬁrst of database to 1, 2015. No
language restriction was applied. We included randomized clinical trials
testing Tongxinluo capsule against western medicine, Tongxinluo capsule
versus placebo, Tongxinluo capsule combined with western medicine
versus western medicine and Tongxinluo capsule combined with western
medicine versus western medicine combined with placebo. Study selec-
tion, data extraction, quality assessment, and data analyses were con-
ducted according to the Cochrane standards.
RESULTS 30 trials with 2903 participants were included. The methodo-
logical quality of the included trials was evaluated as generally low. The
BP-lowering effect of Tongxinluo capsule plus western medicine was
signiﬁcantly higher than that of western medicine (SBP: -4.19, -5.70 to
-2.68, P<0.00001, DBP: -2.43, -3.77 to -1.08, P¼0.0004) or western medi-
cine combined with placebo (SBP: -1.95, -2.37 to -1.53, P<0.00001; DBP:
-0.32, -0.62 to -0.02, P ¼0.04). The BP also decreased signiﬁcantly from
baseline with Tongxinluo capsule than placebo (SBP: -9.40, -10.90 to
-7.90, P < 0.00001; DBP: -11.80, -12.40 to -11.20, P < 0.00001) or western
medicine (SBP: -3.90,-4.93 to -2.87, P < 0.00001; DBP: -3.70, -3.83 to -3.57,
P < 0.00001).12 trials reported adverse events without details.
CONCLUSIONS The current clinical evidence is not of sufﬁcient
quality for wider application of Tongxinluo capsule to be recom-
mended for the treatment of hypertension, and further large, rigor-
ously designed trials are warranted.
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OBJECTIVES To evaluation the efﬁcacy and safety of Traditional
Chinese medicine injections in patients with AMI.
METHODS We searched the Cochrane library (Issue 4, 2011), Pubmed
(1966 to 2011), EMbase (1978 to 2011), CBM (1979 to 2011), CNKI (1979 to
2011) and VIP (1989 to 2011). Randomized controlled trials (RCTs)
comparing either Traditional Chinese Medicine injections only or routine
treatment plus Traditional Chinese Medicine injections with routine
treatment or placebo or no intervention were included. Study selection
and meta-analysis were conducted according to the Cochrane Handbook
for systematic review. Data were extracted from these trials by 3 reviewers
independently and analyzed by RevMan5.1 software.
RESULTS Twenty-one trials involving a total of 1713 AMI patients were
included. The studies provided support of a beneﬁt of Traditional Chinese
Medicine injections combined with routine therapy for reducing the
incidence of mortality [RR¼0.53, 95% CI(0.30, 0.93), P¼0.03], arrhythmia
[RR¼0.42, 95%CI (0.22, 0.80), P¼0.008], heart failure [RR¼0.31, 95%
CI(0.16, 0.61), P¼0.0007] when compared to routine therapy. No evidence
was found for superiority of Traditional Chinese Medicine injections
combined with routine therapy for increasing the rate of recanalization
and reducing the incidence of cardiogenic shock compared to routine
therapy. No serious adverse events were reported.CONCLUSIONS This systematic review found that Traditional Chi-
nese medicine injections in combination with routine therapy may be
a useful treatment to reduce the mortality, arrhythmia and heart
failure of AMI. Due to the methodological limitations of the studies,
the evidence is insufﬁcient to make any conclusive recommendations
about the use of this treatment for patients presenting with AMI.
Large high quality randomized controlled trials are required.
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OBJECTIVES To evaluate the association between the G534A poly-
morphism in the 11-bHSD gene and susceptibility to essential hyper-
tension (EH).
METHODS Based on comprehensive searches of PubMed, Embase,
Google Scholar, CBM, CNKI, WF and CQVIP databases, we identiﬁed
and abstracted outcome data from all articles before March 2015. The
pooled odds ratios (ORs) with 95% conﬁdence intervals (CIs) were
performed in all genetic models. Fixed or random effects model was
separately used depending on the heterogeneity between studies.
Publication bias was tested by Egger’s linear regression approach and
Begg rank correlation test.
RESULTS A total of 1969 cases and 1126 controls accorded inclusion criteria
for detailed analysis. Result in all genetic models: (allelic model: G vs. A :
OR ¼ 0.996, 95%CI¼0.924-1.074, P¼0.916;co-dominant model: GGvs. AA:
OR ¼ 1.022,95%CI¼0.889-1.131, P¼0.968; dominant model: GGþGA
vs.AA:OR¼1.002,95%CI¼0.894-1.124, P¼0.970;recessive model: GGvs.
GAþAA :OR ¼ 1.003, 95 % CI ¼ 0.900-1.117, P¼0.963), all P values>0.05.
CONCLUSIONS The present meta-analysis suggested that 11-bHD
gene-G534A polymorphism was unlikely contribute to essential
hypertension susceptibility.
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OBJECTIVES To systematically assess the current clinical evidence of
Zhigancao (ZGC) Decoction for premature ventricular contractions
(PVCs).
METHODS ll been me and e databases nce.rm adverse eventsSearch
Strategy: PubMed, the Cochrane Center Controlled Trials Register,
EMBASE, Chinese National Knowledge Infrastructure, Chinese Scientiﬁc
Journal Database, and Wanfang Med Online Database were searched until
June 2014. We included randomized clinical trials testing ZGC Decoction
against anti-arrhythmic drugs, ZGC Decoction combined with anti-
arrhythmic drugs versus anti-arrhythmic drugs alone. Study selection, data
extraction, quality assessment, and data analyses were conducted ac-
cording to the Cochrane standards. A meta-analysis of improving total
effects and reducing number of ventricular premature beats was per-
formed to evaluate the effects of ZGC Decoction on PVCs.
RESULTS A total of 25 studies (involving 2441 patients) were included.
The methodological quality of the included trials was evaluated as
generally low. The results of the meta-analysis showed that ZGC
Decoction combined with anti-arrhythmic drugs had signiﬁcant effect on
improving total effects (RR: 1.30 [1.22, 1.38]; P < 0.00001) and relieving
number of ventricular premature beats (MD: -6.66 [-12.94, -0.37];
P¼0.04) compared with anti-arrhythmic drugs alone. Our review showed
that ZGC Decoction was more effective in improving total effects (RR: 1.22
[1.08, 1.37]; P¼0.0009), compared with anti-arrhythmic drugs alone. 13
trials reported adverse events, while the others did not mention them,
indicating that the safety of ZGC Decoction remains uncertain.
CONCLUSIONS ZGC Decoction appears to have beneﬁcial effects
on improvement of total effects, reduction of number of ventricular
premature beats in participants with PVCs. However, further
thorough investigation, large-scale, proper study designed, randomized
trials of ZGC Decoction for PVCs will be required to justify the effects
reported.
